Publications by authors named "Margarita Marin"
Article Synopsis
- The ORZORA trial tested the effectiveness and safety of olaparib as a maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer who have BRCA mutations or non-BRCA homologous recombination repair mutations after prior chemotherapy.
- The study involved 177 patients who received olaparib, with a median follow-up showing progression-free survival rates varying between 16.4 and 19.3 months depending on mutation type.
- Results indicated that most patients with BRCA mutations either improved or maintained their quality of life, and the safety profile of olaparib was consistent with expectations, reinforcing its use for these patients.
Article Synopsis
- Mirvetuximab soravtansine (MIRV) is a new treatment targeting folate receptor α (FRα) for patients with platinum-resistant epithelial ovarian cancer (PROC), evaluated in the SORAYA study.
- The study involved 106 patients, primarily with advanced treatment histories, finding an objective response rate (ORR) of 32.4% with a median response duration of 6.9 months.
- While MIRV showed promising efficacy, common side effects included blurred vision, keratopathy, and nausea, which sometimes led to treatment modifications for nearly half of the patients.
Background: The coronavirus disease (COVID-19) pandemic has already affected more than 400 million people, with increasing numbers of survivors. These data indicate that a myriad of people may be affected by pulmonary sequelae of the infection. The aim of this study was to evaluate pulmonary sequelae in patients with bilateral COVID-19 pneumonia according to severity 1 year after hospital discharge.
View Article and Find Full Text PDFObjective: Progression-free survival (PFS) is an important early efficacy endpoint in ovarian cancer (OC) and its relevance to patients should be assessed. PRIMA, a phase III trial, assessed niraparib in patients with OC; this post hoc analysis examined the relationship between disease progression in OC and health-related quality of life (HRQoL).
Methods: The PRIMA trial randomized patients with advanced OC responsive to first-line platinum-based chemotherapy to once daily maintenance oral niraparib or placebo.
The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (≥300 cells·μL) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.
View Article and Find Full Text PDFBackground: The Cerambycidae are one of the largest beetle families. Cerambycid beetles are found on all continents, but the tropics are extremely rich in this species. The genus Criodion (Audinet-Serville, 1833) includes 13 species in the Neotropical Region, two of which occur in Central America.
View Article and Find Full Text PDFDifferential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD.
Chest
July 2015
Article Synopsis
- - The study aimed to evaluate how well the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), and Modified Medical Research Council (mMRC) dyspnea scores predict mortality in patients with Chronic Obstructive Pulmonary Disease (COPD).
- - Researchers analyzed data from 768 COPD patients over an average follow-up of 38 months, finding that higher scores on all three assessments were linked to increased mortality.
- - Although the CAT and CCQ have similar predictive abilities for all-cause mortality, they were not as effective as the mMRC dyspnea scores, leading to suggestions for new scoring thresholds for better risk assessments.
Rationale: Little is known about the longitudinal changes associated with using the 2013 update of the multidimensional GOLD strategy for chronic obstructive pulmonary disease (COPD).
Objective: To determine the COPD patient distribution of the new GOLD proposal and evaluate how this classification changes over one year compared with the previous GOLD staging based on spirometry only.
Methods: We analyzed data from the CHAIN study, a multicenter observational Spanish cohort of COPD patients who are monitored annually.
Background: This study aimed to identify tuberculosis transmission patterns in Castellón in a period of major demographic changes.
Methods: A prospective study of patients with positive culture in the province of Castellon over a 4-year period (2004-2007) was carried out. Cases were described by year and nationality and were compared with those reported to the Department of Public Health.